Genetics and Cellular Signaling in Cancer: Unraveling the Molecular Mechanisms

Asma Abdullwahab Khalifa
Higher Institute of Medical Sciences and Technology/abusleem

Abstract

Cancer is a complex disease that arises due to the accumulation of genetic alterations and dysregulation of cellular signaling pathways. The understanding of genetics and cellular signaling in cancer has provided crucial insights into the underlying molecular mechanisms that drive carcinogenesis and has paved the way for the development of targeted therapies. This article aims to provide a comprehensive overview of the current knowledge and the latest accessible research findings regarding the interplay between genetics and cellular signaling in cancer.

Keywords: cancer, genetics, cellular signalling, carcinogenesis

Introduction

Cancer is a complex disease caused by genetic and/or epigenetic changes in one cell or a group of cells. These alterations disrupt normal cell function and cause cancerous cells to hyper proliferate and avoid mechanisms that would typically control their growth, division, and migration[1]. Many of these disruptions map to specific cell signaling pathways[1].

Genetic mutations in key regulatory genes, such as tumor suppressor genes and oncogenes, play a central role in cancer development. Additionally, dysregulation of cellular signaling pathways, which control various cellular processes including proliferation, differentiation, and apoptosis, further contribute to tumor formation and progression.

Cellular signaling is the process by which cells communicate with each other to coordinate their activities. Aberrant signaling of just one pathway can have huge implications on wider signaling networks that consequently promote cancer progression and metastasis[1].

Cell signaling is a complex process by which cells communicate with each other to coordinate various physiological functions and maintain proper cellular homeostasis. It involves the transmission of information from one cell to another through the use of signaling molecules and receptors. These signals can be chemical, electrical, or mechanical in nature, and they help regulate cellular processes such as growth, development, differentiation, metabolism, and response to environmental cues.

Cell signaling can occur through various mechanisms, including direct cell-to-cell communication, paracrine signaling (where cells release signaling molecules that act locally on nearby cells), endocrine signaling (where signaling molecules are released into the bloodstream to act on distant cells), and synaptic signaling (where neurons communicate with each other through synapses).

The signaling process typically involves three main components: a signaling molecule (ligand), a receptor, and an effector molecule or cellular response. The ligand, which could be a hormone, neurotransmitter, growth factor, or a variety of other molecules, binds to a specific receptor on the cell surface or within the cell. This binding triggers a series of cellular events known as signal transduction, which amplifies and relays the signal to the effector molecule or signaling pathway[2].

Signal transduction pathways involve a network of proteins, enzymes, and second messengers that help transmit and interpret the signal within the cell. These pathways often involve key components such as protein kinases, which phosphorylate proteins to activate or deactivate them, and transcription factors, which regulate gene expression. The ultimate response of the cell to the signaling event can vary and may include changes in gene expression, enzyme activity, ion channel opening, cytoskeletal rearrangement, or secretion of specific molecules[2].

Importantly, cell signaling is tightly regulated to ensure the proper functioning of cellular processes. Cells have mechanisms to control the duration and intensity of the signal, as well as to terminate the signal once the desired response is achieved. Dysregulation of cell signaling pathways can contribute to various diseases, including cancer, neurodegenerative disorders, and autoimmune conditions[2][3].

Understanding how these signaling networks function in vivo and how they are altered in cancer cells represents a major intellectual challenge, In this paper, we will discuss the cellular signaling in cancer and their role in the carcinogenesis mechanisms.

The major cancer- related signalling pathways

Aberrant signaling of just one pathway can have huge implications on wider signaling networks that consequently promote cancer progression and metastasis[4].

Once the receptors have activated their first substrate, a signalling pathway is activated. Because of their fundamental role in transmitting signals that regulate all the cell functions, these signalling pathways are widely involved in neoplastic growth[3].

In cancer either the signals reaching the cell or the pathways themselves can be altered, that result in a dysregulated signaling which can escape the normal control mechanisms[3].

The major signaling pathways involved in cancer development include the MAPK/ERK pathway, PI3K/AKT/mTOR pathway, JAK/STAT pathway, and Wnt/β-catenin pathway.

The MAPK/ERK pathway

The MAPK/ERK pathway, also known as the Ras-Raf-MEK-ERK pathway, is a chain of proteins in the cell that communicates a signal from a receptor on the surface of the cell to the DNA in the nucleus of the cell[2]. The pathway plays an important role in controlling various physiological processes in cells, such as cell growth, development, division, and death[5][6]. The key components and steps of the MAPK/ERK pathway includes:

1. Receptor Activation: The signal that starts the MAPK/ERK pathway is the binding of extracellular mitogen to a cell surface receptor. This allows a Ras protein (a Small GTPase) to swap a GDP molecule for a GTP molecule, flipping the "on/off switch" of the pathway[2].
2. Ras Activation: The Ras protein can then activate MAP3K (e.g., Raf), which activates MAP2K, which activates MAPK. This then leads to a series of phosphorylation events downstream in the MAPK cascade (Raf-MEK-ERK) ultimately resulting in the phosphorylation and activation of ERK[2][7].
3. Transcription Factor Activation: The phosphorylation of ERK results in an activation of its kinase activity and leads to phosphorylation of its many downstream targets involved in regulating cellular biological functions, such as cell proliferation,

cell differentiation, cell cycle regulation, cell apoptosis, and tissue formation[5][6]. ERK1/2 at the terminal kinases in MAPK signaling can translocate to the nucleus to regulate transcription programs, and mediate growth, migration, and differentiation[5]. Mutations in genes and proteins involved in the MAPK/ERK pathway can lead to dysregulation of the pathway, promoting uncontrolled cell proliferation and tumor growth. Understanding the MAPK/ERK pathway is crucial for the development of targeted therapies that can specifically inhibit or modulate this pathway to halt cancer progression.



Figure 1: The MAPK/ERK pathway (from https://www.genecopoeia.com)

The PI3K/Akt/mTOR pathway

The PI3K/Akt/mTOR pathway plays a crucial role in the development and progression of cancer. This signaling cascade is involved in various cellular processes, including cell growth, proliferation, survival, and metabolism. Dysregulation or aberrant activation of this pathway has been implicated in a wide range of cancers.

The mechanism of involvement begins with the activation of phosphoinositide 3-kinase (PI3K), which is triggered by various growth factors, receptor tyrosine kinases, and oncogenes. PI3K catalyzes the production of phosphatidylinositol 3,4,5-trisphosphate (PIP3) from phosphatidylinositol 4,5-bisphosphate (PIP2) at the cell membrane. PIP3 serves as a docking site, recruiting Akt (also known as protein kinase B) to the plasma membrane[8].

Once recruited, Akt is phosphorylated and activated by phosphoinositide-dependent kinase 1 (PDK1) and mammalian target of rapamycin complex 2 (mTORC2). Activated Akt translocates into the cytoplasm and nucleus, where it phosphorylates a myriad of target proteins involved in various cellular functions.

One of the primary downstream targets of Akt is the mechanistic target of rapamycin (mTOR), which exists in two complexes: mTORC1 and mTORC2. Activated Akt phosphorylates and inhibits the tuberous sclerosis complex 2 (TSC2) protein, leading to the activation of mTORC1. Active mTORC1 promotes protein synthesis, cell growth, and proliferation by phosphorylating downstream effectors like ribosomal protein S6 kinase (S6K) and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1)[9].

mTORC1 also plays a pivotal role in promoting angiogenesis, a process crucial for tumor growth and metastasis. It upregulates vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1-alpha (HIF-1α), which promote the formation of new blood vessels to supply nutrients and oxygen to the growing tumor.

Additionally, the PI3K/Akt/mTOR pathway regulates cell survival and apoptosis by modulating the expression and activity of anti-apoptotic proteins like Bcl-2 and Bcl-xL and pro-apoptotic proteins like Bad.

The dysregulation of the PI3K/Akt/mTOR pathway frequently occurs in cancers through different mechanisms, such as activating mutations in PI3K or Akt, loss of function mutations in the phosphatase and tensin homolog (PTEN) tumor suppressor gene, and overexpression or amplification of growth factor receptors (e.g., EGFR, HER2). These alterations lead to sustained activation of the pathway, promoting uncontrolled cell growth, survival, and resistance to apoptosis[3].



Figure 2: The PI3K/Akt/mTOR pathway. (from https://www.researchgate.net)

The JAK/STAT pathway

The JAK/STAT pathway plays a significant role in carcinogenesis, contributing to cancer progression and

development. The mechanism by which JAK/STAT pathway is involved in carcinogenesis includes:

1. Activation of JAK/STAT pathway: The JAK-STAT pathway is activated by various hormones, cytokines, and growth factors[10]. Janus tyrosine kinases (JAKs) are associated with cytokine receptors and mediate tyrosine phosphorylation of receptors, leading to the recruitment and activation of STAT (Signal Transducers and Activators of Transcription) proteins[11]. This activation initiates a cascade of signaling events.

2. Regulation of gene transcription: Once activated, STAT proteins are phosphorylated and form dimers that translocate to the nucleus. In the nucleus, they bind to specific DNA sequences and regulate the transcription of target genes involved in cell proliferation, survival, and immune response[11].

3. Tumor growth and metastasis: Dysregulation of the JAK/STAT pathway can contribute to tumor growth and metastasis. Abnormal activation of the pathway can lead to uncontrolled cell proliferation, inhibition of apoptosis, and promotion of angiogenesis[12]. The JAK/STAT pathway can also modulate the tumor microenvironment and promote immune evasion by suppressing anti-tumor immune responses[13].

4. Involvement in specific cancers: The JAK/STAT pathway has been implicated in various types of cancer, including cholangiocarcinoma, myeloproliferative neoplasms, and solid tumors[10][12][13]. In some cancers, the activation of the JAK/STAT pathway is a driver of cancer growth and metastasis. However, the extent to which the pathway activation contributes to oncogenesis in different cancers is still being studied.



Figure 3: The JAK/STAT pathway. (from https://www.rockland.com)

The Wnt/β-catenin pathway

The Wnt/β-catenin signaling pathway, also called the canonical Wnt signaling pathway, is a highly conserved signaling axis participating in diverse physiological processes such as proliferation, differentiation, apoptosis, migration, invasion and tissue homeostasis.Dysregulation of the Wnt/β-catenin cascade has been implicated in the development and progression of various types of cancers[14][15].

The molecular mechanisms of the Wnt/β-catenin pathway in carcinogenesis includes:

1. Activation of the pathway: The Wnt/β-catenin pathway is activated by the binding of extracellular Wnt ligands to Frizzled receptors and LRP5/6 co-receptors. This binding leads to the stabilization and nuclear translocation of β-catenin, which then interacts with TCF/LEF transcription factors to activate the transcription of target genes involved in cell proliferation, survival, and differentiation[14][15].

2. Regulation of gene transcription: In the absence of Wnt ligands, β-catenin is phosphorylated by the destruction complex, which includes APC, Axin, GSK3β, and CK1α[14]. This phosphorylation targets β-catenin for ubiquitination and proteasomal degradation. However, in the presence of Wnt ligands, the destruction complex is inhibited, leading to the accumulation of β-catenin in the cytoplasm and its translocation to the nucleus. In the nucleus, β-catenin interacts with TCF/LEF transcription factors to activate the transcription of target genes involved in cell proliferation, survival, and differentiation[16].

3. Tumor growth and metastasis: Dysregulation of the Wnt/β-catenin pathway can contribute to tumor growth and metastasis. Abnormal activation of the pathway can lead to uncontrolled cell proliferation, inhibition of apoptosis, and promotion of angiogenesis. The Wnt/β-catenin pathway can also modulate the tumor microenvironment and promote immune evasion by suppressing anti-tumor immune responses[17].

4. Involvement in specific cancers: The Wnt/β-catenin pathway has been implicated in various types of cancer, including pancreatic cancer, oral cancer, and melanoma. In some cancers, the activation of the Wnt/β-catenin pathway is a driver of cancer growth and metastasis. However, the extent to which the pathway activation contributes to oncogenesis in different cancers is still being studied[15].



Figure 4: The Wnt/β-catenin signaling pathway. (from https://jhoonline.biomedcentral.com)

Conclusion

The extensive research on genetics and cellular signaling in cancer has significantly enhanced our understanding of the underlying molecular mechanisms driving carcinogenesis. Unraveling the complex interplay between genetic alterations and dysregulated signaling pathways has not only improved diagnostics but also guided the development of targeted therapies. Further investigation into these intricate interactions will open new avenues for personalized and more effective cancer treatments in the future.

References

1. Lansdowne, L. E. Cell Signaling in Cancer Article Published: December 17, 2018.

2. Pecorino, L. (2021). *Molecular biology of cancer: mechanisms, targets, and therapeutics*. Oxford university press.

3. Pezzella, F., Tavassoli, M., & Kerr, D. J. (Eds.). (2019). *Oxford textbook of cancer biology*. Oxford University Press.

4. Sever, R., & Brugge, J. S. (2015). Signal transduction in cancer. *Cold Spring Harbor perspectives in medicine*, *5*(4).

5. Guo, Y., Pan, W., Liu, S., Shen, Z., Xu, Y., & Hu, L. (2020). ERK/MAPK signalling pathway and tumorigenesis (Review). Experimental and Therapeutic Medicine, 19, 1997-2007. https://doi.org/10.3892/etm.2020.8454

6. Guo, Y. J., Pan, W. W., Liu, S. B., Shen, Z. F., Xu, Y., & Hu, L. L. (2020). ERK/MAPK signalling pathway and tumorigenesis. *Experimental and therapeutic medicine*, *19*(3), 1997-2007.

7. ZHANG, W., & LIU, H. T. (2002). MAPK signal pathways in the regulation of cell proliferation in mammalian cells. *Cell Research*, *12*(1), 9-18. https://doi.org/10.1038/sj.cr.7290105

8. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550-562.

9. Kennedy, B. K., & Lamming, D. W. (2016). The mechanistic target of rapamycin: the grand conducTOR of metabolism and aging. *Cell metabolism*, *23*(6), 990-1003.

10. Smirnova, O. V., Ostroukhova, T. Y., & Bogorad, R. L. (2007). JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression. *World Journal of Gastroenterology: WJG*, *13*(48), 6478.

11. Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021). The JAK/STAT signaling pathway: From bench to clinic. *Signal Transduction and Targeted Therapy*, *6*(1), 1-33. https://doi.org/10.1038/s41392-021-00791-1

12. Brooks, A. J., & Putoczki, T. (2020). JAK-STAT Signalling Pathway in Cancer. *Cancers*, *12*(7). https://doi.org/10.3390/cancers12071971

13. Owen, K. L., Brockwell, N. K., & Parker, B. S. (2019). JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression. *Cancers*, *11*(12), 2002. https://doi.org/10.3390/cancers11122002

14. Zhang, Y., & Wang, X. (2020). Targeting the Wnt/β-catenin signaling pathway in cancer. *Journal of Hematology & Oncology*, *13*. https://doi.org/10.1186/s13045-020-00990-3

15. Zhang, Y., & Wang, X. (2020). Targeting the Wnt/β-catenin signaling pathway in cancer. *Journal of hematology & oncology*, *13*, 1-16.

16. Reyes, M., Flores, T., Betancur, D., Peña-Oyarzún, D., & Torres, V. A. (2020). Wnt/β-Catenin Signaling in Oral Carcinogenesis. *International Journal of Molecular Sciences*, *21*(13). https://doi.org/10.3390/ijms21134682

17. Luke, J. J., Bao, R., Sweis, R. F., Spranger, S., & Gajewski, T. F. (2019). WNT/β-catenin pathway activation correlates with immune exclusion across human cancers. *Clinical Cancer Research*, *25*(10), 3074-3083.